NovoCure (NVCR) Net Cash Flow Growth (3y) (2017 - 2026)
NovoCure (NVCR) Net Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.65 Bn | 175.35 Bn | 6.27 Bn | -32.51% |
| 2 | Stryker | 128.95 Bn | 126.08 Bn | 3.81 Bn | -87.87% |
| 3 | Medtronic | 108.30 Bn | 99.08 Bn | 6.41 Bn | 31.32% |
| 4 | Boston Scientific | 68.31 Bn | 66.85 Bn | 3.61 Bn | -11.49% |
| 5 | Edwards Lifesciences | 48.19 Bn | 44.52 Bn | 1.29 Bn | -87.88% |
| 6 | Dexcom | 28.33 Bn | 27.21 Bn | 750.30 Mn | 129.29% |
| 7 | GE HealthCare Technologies | 28.02 Bn | 25.74 Bn | 1.98 Bn | -65.12% |
| 8 | Smith & Nephew | 26.97 Bn | 26.39 Bn | - | - |
| 9 | Koninklijke Philips | 24.06 Bn | 20.93 Bn | 2.07 Bn | -48.90% |
| 10 | NovoCure | 2.02 Bn | 1.58 Bn | 142.48 Mn | 30.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 30.38% |
| Mar 31, 2026 | -27.73% |
| Dec 31, 2025 | -23.40% |
| Sep 30, 2025 | 52.66% |
| Jun 30, 2025 | -49.70% |
| Mar 31, 2025 | -27.13% |
| Dec 31, 2024 | 63.72% |
| Sep 30, 2024 | -60.29% |
| Jun 30, 2024 | -117.89% |
| Mar 31, 2024 | 39.06% |
| Dec 31, 2023 | 100.21% |
| Sep 30, 2023 | -26.48% |
| Jun 30, 2023 | -58.37% |
| Mar 31, 2023 | 176.49% |
| Dec 31, 2022 | -60.22% |
| Sep 30, 2022 | -85.50% |
| Jun 30, 2022 | 84.70% |
| Mar 31, 2022 | -52.39% |
| Dec 31, 2021 | -208.45% |
| Sep 30, 2021 | 238.19% |